VEXAS syndrome has an unmet need for therapeutic interventions. Even if few data exist
regarding the treatment of this newly described syndrome, different options can be proposed …

Acquired aplastic anemia (AA) and paroxysmal nocturnal hemoglobinuria (PNH) are
pathogenically related nonmalignant bone marrow failure disorders linked to T-cell …

Severe aplastic anemia (SAA) is a stem cell disorder often treated with bone marrow
transplantation (BMT) to reconstitute hematopoiesis. Outcomes of related HLA …

Patients with severe aplastic anemia (SAA) are either treated with bone marrow transplant
(BMT) or immunosuppression (IST) depending on their age, comorbidities, and available …

The progress in aplastic anaemia (AA) management is one of success. Once an obscure
entity resulting in death in most affected can now be successfully treated with either …

Eltrombopag, an FDA-approved non-peptidyl thrombopoietin receptor agonist, is clinically
used for the treatment of aplastic anemia, a disease characterized by hematopoietic stem …

Myelodysplastic syndromes (MDS) are a group of clonal myeloid disorders characterized by
low blood counts and a propensity to develop acute myeloid leukemia. The management of …

Acquired aplastic anemia (AA) is characterized by a reduced stem cell reserve. Several
preclinical studies have confirmed the beneficial effect of thrombopoietin (TPO) on the …

Acquired severe aplastic anaemia (SAA) has an immune pathogenesis, and
immunosuppressive therapy (IST) with anti‐thymocyte globulin and cyclosporine is effective …

Aplastic anemia (AA) is the prototypic bone marrow failure syndrome and can be classified
as either acquired or inherited. Inherited forms are due to the effects of germline mutations …